Iktos
Philip Laut is an experienced executive in sales and business development, currently serving as Vice President, Head of US Operations, Sales & Business Development at Iktos since July 2023. Previously, Laut held the position of Vice President of Biopharma at Nanome Inc., overseeing relationships with major global pharmaceutical companies. Prior experiences include roles such as Director of Business Development at Revenew International, where Laut developed sales channels into big pharma, and Director of Global Accounts at Colorcon®, managing significant global accounts and improving profitability. Laut's extensive background in various leadership roles spans multiple industries, including pharmaceuticals and specialty chemicals, complemented by a robust educational foundation in Materials Sciences and Engineering, as well as Marketing.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.